Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 11/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493136 | 0.81 | CETP (0.51) | CETPSGMS1SGMS2 | |
| SCHEMBL4494930 | 0.78 | CETP (0.41) | CETPTACR1CYP1A2CYP2D6 | |
| SCHEMBL1587844 | 0.78 | SLC6A4 (0.43) | CETPGPBAR1 | |
| SCHEMBL4490319 | 0.78 | CETP (0.45) | CETPSGMS1SGMS2 | |
| SCHEMBL4495620 | 0.76 | CETP (0.40) | CETPGPBAR1 | |
| SCHEMBL132751 | 0.76 | ALDH1A1 (0.40) | CETPTACR1GPBAR1 | |
| SCHEMBL4504221 | 0.75 | CETP (0.40) | CETP | |
| SCHEMBL4506070 | 0.71 | CETP (0.53) | CETPTACR1SGMS1SGMS2 | |
| SCHEMBL4503976 | 0.70 | CETP (0.42) | CETPTACR1GPBAR1LMNACYP1A2 | |
| SCHEMBL4497887 | 0.70 | CETP (0.38) | CETPTACR1GPBAR1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885TACR1 3300/4885GPBAR1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.